Pedersen NP, Vaughan CW, Christie MJ. Opioid receptor modulation of GABAergic and serotonergic spinally projecting neurons of the rostral ventromedial medulla in mice. J Neurophysiol 106: 731-740, 2011. First published May 18, 2011 doi:10.1152/jn.01062.2010.-The rostral ventromedial medulla (RVM) is an important site of opioid actions and forms part of an analgesic pathway that projects to the spinal cord. The neuronal mechanisms by which opioids act within this brain region remain unclear, particularly in relation to the neurotransmitters GABA and serotonin. In the present study, we examined serotonergic and GABAergic immunoreactivity, identified using immunohistochemistry for tryptophan hydroxylase (TPH) and glutamate decarboxylase (GAD), in combination with in vitro whole cell patch clamping to investigate the role of opioids on the mouse RVM with identified projections to the spinal cord. Tyr-D-Ala-Gly-N-Me-Phe-Gly-ol enkephalin (DAMGO) produced -opioid receptor-mediated outward currents in virtually all TPH-immunoreactive projecting neurons and GADimmunoreactive nonprojecting neurons (87% and 86%). The other groups of RVM neurons displayed mixed responsiveness to DAMGO (40-68%). Deltorphin II and U-69593 produced ␦-and -opioid receptor-mediated outward currents in smaller subpopulations of RVM neurons, with many of the ␦-opioid responders forming a subpopulation of -opioid-sensitive GABAergic nonprojecting neurons. These findings are consistent with prior electrophysiological and anatomic studies in the rat RVM and indicate that both serotonergic and GABAergic RVM neurons mediate the actions of -opioids. Specifically, -opioids have a direct postsynaptic inhibitory influence over both GABAergic and serotonergic neurons, including those that project to the dorsal spinal cord.
THE ROSTRAL VENTROMEDIAL MEDULLA (RVM) forms part of a descending pathway that is an important site for the supraspinal antinociceptive actions of opioids (Fields 2004) . Microinjection of -and ␦-opioid receptor agonists into the RVM produces antinociception (Dickenson et al. 1979; Hurley et al. 2003; Ossipov et al. 1995; Rossi et al. 1994; Satoh et al. 1983; Thorat and Hammond 1997) , and the antinociception produced by -opioids is reversed by -opioid receptor agonists (Ackley et al. 2001; Meng et al. 2005 , Pan et al. 1997 . The antinociceptive actions of opioids are associated with reciprocal changes in the action potential activity of subpopulations of RVM neurons, including on-cells, off-cells, and neutral-cells, which exhibit increased, decreased, or no change in discharge, respectively, immediately before tail flick during noxious heating of the tail in lightly anaesthetized rats (Fields et al. 1983 ).
-Opioids inhibit on-cells and excite off-cells, whereas -opioids inhibit both on-cells and a proportion of off-cells (Ackley et al. 2001; Meng et al. 2005 ). These observations suggest that on-cells are opioid-sensitive GABAergic interneurons that inhibit off-cells within the RVM (Fields et al. 1991) .
More recent evidence has suggested that on-and off-cells modulate nociception via a more complex mechanism involving parallel descending pathways to the spinal dorsal horn (Cleary et al. 2008; Fields et al. 1991; Heinricher et al. 2009 ). For example, cessation of off-cell activity usually precedes on-cell firing (Cleary et al. 2008) , and both on-cells and off-cells project directly to the spinal cord dorsal horn (Fields et al. 1995; Vanderhorst and Ulfhake 2006) , as do many RVM GABAergic neurons (Antal et al. 1996; Jones et al. 1991; Millhorn et al. 1988; Stornetta and Guyenet 1999) . In addition, the majority of both on-cells and off-cells are GABAergic (Morgan et al. 2008; Winkler et al. 2006 ). However, it remains to be determined whether in vivo responses to -opioid agonists are related to neurochemical types of RVM neurons.
In rats, distinct primary and secondary RVM neurons have been identified in vitro that superficially display similarities to the on-and off-cells observed in vivo (Pan et al. 1990 (Pan et al. , 1993 (Pan et al. , 1997 . Primary neurons are mainly serotonergic, not directly inhibited by -opioid agonists, and receive opioid-sensitive GABAergic inputs, whereas secondary neurons are mainly nonserotonergic and directly inhibited by -opioids. Primary neurons are, however, unlikely to be off-cells because serotonergic RVM neurons observed in vivo are neither on-cells nor off-cells, do not respond uniformly to morphine (Gao et al. 1997 (Gao et al. , 1998 Potrebic et al. 1994) , and may express both -and -opioid receptors (Kalyuzhny et al. 1996; Kalyuzhny and Wessendorf 1999; Marinelli et al. 2002) . More recent in vitro studies have shown that -opioids directly inhibit subpopulations of spinally projecting serotonergic and nonserotonergic RVM neurons, whereas -opioids inhibit a small subpopulation of serotonergic RVM-projecting neurons (Marinelli et al. 2002; Zhang and Hammond 2010; Zhang et al. 2006) . Thus, the relationship between the in vivo properties of RVM neurons to those observed in vitro remains unclear, as does the role of the different neurochemical phenotypes in opioid-mediated actions within the RVM. This study sought to determine the relationship between postsynaptic opioid responsiveness and other physiological properties with GABAergic and serotonergic phenotypes in spinally projecting and nonprojecting mouse RVM neurons in vitro. Mice were studied in the context of the increasing use of genetically modified mice, including to study RVM anatomy (for example, Braz and Basbaum 2008), with comparative cellular physiology, pharmacology, and cellular properties not always qualitatively comparable between rats and mice (for example, Margolis et al. 2008) . The membrane properties and opioid responses of mouse RVM neurons were similar to those reported previously in the rat. -Opioid agonists inhibited most spinally projecting GABAergic and serotonergic neurons as well as nonprojecting GABAergic neurons.
-and ␦-opioids acted on small subpopulations of GABAergic and serotonergic neurons, but -opioids more selectively inhibited serotonergic neurons than GABAergic neurons.
METHODS
Animals. C57/bl6 male and female mice (Gore Hill Animal Laboratories, Royal North Shore Hospital) were kept on a 12:12-h lightdark cycle at 23°C with freely available food and water. Experiments were performed in the light phase. All experiments followed the guidelines of the National Health Medical Research Council Code of Practice for the Care and Use of Animals in Research in Australia and were approved by the Animal Care and Ethics Committee of Royal North Shore Hospital.
Retrograde tracer injection. Some mice [postnatal day (P)9 -13] were anesthetized with halothane (1-2% in 100% O 2 ), and an incision was made along the midline from the intrascapular region to just below the last pair of ribs. The lumbar spinal cord was exposed by the removal of two laminae, the dura was opened, and fluorescent nanospheres [0.04 m, red-orange (565/580 nm) carboxylate-modified microspheres, Molecular Probes, Eugene, OR] were microinjected via a glass micropipette (diameter: 15-20 m) mounted on a micromanipulator angled at 45°toward the head. Two to three superficial injections (surface of the spinal cord was penetrated as shallowly as possible) per side (5 nl) were made bilaterally into the spinal cord dorsal horn (T13-L1) using a using a calibrated injection system (Drummond Nanoject, Broomall, PA). The overlying muscles and skin were then separately sutured, the incision was cleaned, and topical antibiotic was applied. Animals were allowed to recover from anesthesia in a warmed box before being returned to holding cages with their mother and littermates. Two to five days after surgery, these animals and other nonoperated littermates were used for in vitro experiments.
Brain slice preparation and recording. Coronal brain slices (210 m thick) were prepared from P7-22 mice (age: P16.5 Ϯ 0.3, n ϭ 104 animals). Slices were cut in ice-cold artificial cerebrospinal fluid [aCSF; containing (in mM) 126 NaCl, 2.5 KCl, 1.4 NaH 2 PO 4 , 1.2 MgCl 2 , 2.4 CaCl 2 , 11 glucose, and 25 NaHCO 3 ] using a vibrating microtome (Leica VT1000S) and maintained at 34°C in a submerged chamber containing aCSF equilibrated with a mixture of 5% CO 2 and 95% O 2 . Individual slices were then transferred to a chamber on an upright microscope (Olympus BX50, Olympus, Sydney, NSW, Australia) and superfused continuously (2 ml/min) with aCSF at 34°C. RVM neurons were visualized using infrared Nomarski optics in the triangular midline region dorsal to the pyramidal tracts, rostral to the inferior olive, including and immediately surrounding the raphe magnus. Retrogradely labeled neurons were identified by switching to fluorescence illumination and then with superimposition with Nomarski optics. Cell-attached and whole cell patch-clamp recordings of membrane currents (holding potential of Ϫ60 mV after liquid junction potential correction) were made using an Axopatch 200B (Molecular Devices, Sunnyvale, CA) with patch electrodes containing (in mM) 115 K-gluconate, 25 KCl, 15 NaCl, 1 MgCl 2 , 10 HEPES, 11 EGTA, 5 MgATP, 0.33 NaGTP, and 0.02% biocytin (pH 7.35, osmolality: 280 -285 mosM) . Series resistance (Ͻ15 M⍀) was compensated by 80% and monitored continuously. Spontaneous action potential frequency was sampled (10 kHz, 5-kHz low-pass filter) before the whole cell recording mode was established to avoid the effects of changing the intracellular milieu on action potential activity. Data from cell-attached and whole cell recordings were only included for analyses if the action potential amplitude was at least 50 mV above threshold after the whole cell recording mode was established to ensure that only highly viable neurons were included. Conductance was determined from the current-voltage relationship within a 20-mV range negative of initial holding voltage (usually Ϫ60 mV). Action potential half-width was defined as the duration (in ms) of the average action potential (usually 10 -20 per average) at the half-maximal amplitude. Whether or not action potentials exhibited an inflection in the rate of repolarization, as previously reported in the rat (Marinelli et al. 2002; Zhang et al. 2006) , was classified if an obvious shoulder was present on the repolarizing phase. Fast afterhypolarizations (AHPs) were classified as previously described (Marinelli et al. 2002; Zhang et al. 2006) by the presence or absence of a rapid (usually Ͻ2 ms from threshold) overshooting hyperpolarization that preceded the slow AHP.
Postsynaptic currents in response to agonist application were sampled at 1 kHz and filtered offline (100-Hz low-pass filter) for analysis using AxographX (Axograph Scientific, Sydney, NSW, Australia). A neuron was considered to respond to an agonist if it produced an outward current of Ͼ5 pA during continuous superfusion that reversed upon washing or application of the appropriate antagonist. Neurons without overshooting action potentials, stable baseline currents, and resting membrane potentials of less than Ϫ50 mV were excluded from further analysis. Neurons failing to respond to any opioid agonist were also excluded if they did not respond to the subsequent application of baclofen (10 M) or nociception/orphanin FQ (0.3-1 M).
Injection site confirmation and immunohistochemical and biocytin staining. Spinal cords from animals with retrograde tracer injections were immersion fixed, cut into 50-m axial sections for examination with fluorescence and dark-field microscopy, and only included in further analyses if injection sites did not include the ventral horn. It should be noted that, in addition to the medulla, neuronal transport of the tracer from injection sites would also be expected locally within the spinal cord. While this might limit clear demarcation of the margins of the initial tracer deposition, most injection sites appeared to be well confined to the superficial dorsal horn.
After being recorded, slices were fixed [phosphate-buffered paraformaldehyde-picric acid solution: 75 mM KH 2 PO 4 , 85 mM Na 2 HPO 4 , 4% (wt/vol) paraformaldehyde, and 14% (vol/vol) saturated aqueous picric acid; pH 6.9] for 30 min before being washed with Tris-buffered saline (0.9% NaCl, 6.1 g/l trizma base, and 0.1% NaN 3 ; pH 7.4), and refrigerated for up to 1 wk. Slices were washed in 0.1 M PBS (pH 7.4) before being placed in 0.1% NaBH 4 at room temperature for 30 min. Nonspecific protein binding was blocked (PBS with 5% normal horse serum and 5% BSA). Slices were incubated in primary antisera [1% BSA; 1:1,000 mouse anti-glutamate decarboxylase (GAD)67, MAB 5406, clone 1G10.2, Chemicon, Temecula, CA; 1:1,000 sheep anti-tryptophan hydroxylase (TPH), AB 1541, Chemicon; 1:500 streptavidin and Alexa fluor 647, S-32357, Molecular Probes] at 4°C for 40 h. GAD67 immunohistochemistry was chosen for the identification of GABAergic neurons, as it is detectable in cell bodies, unlike predominantly terminally located GAD65 (Esclapez et al. 1994) . After being washed, slices were incubated overnight in secondary antibodies (PBS with 1% BSA; 1:500 donkey anti-mouse IgG Alexa fluor 488, A-21202, Molecular Probes; and 1:200 donkey anti-sheep IgG Alexa fluor 546, A-21098, Molecular Probes). Slices were mounted onto gelatinized slides; coverslips were affixed with Fluoromount-G (Electron Microscopy Sciences, Hatfield, PA).
The specificity of GAD staining was confirmed in Purkinje neurons of the cerebellum (not shown) and was appropriately present and absent in other regions where the distribution of GABAergic neurons has been well described, matching the proportion and distribution of GABAergic neurons as previously described in the RVM (for example, Jones et al. 1991) . Immunoreactivity was absent when the primary antibody was omitted.
Image processing and evaluation. A Nikon Eclipse E800 microscope with a Bio-Rad Radiance Plus confocal scanning system and Bio-Rad LaserSharp 2000 (version 5.2) software (Bio-Rad, Hampstead, UK) was used to examine recorded cells. Anatomic images were taken with a ϫ10 or ϫ20 objective, and image stacks were collected to examine immunoreactivity with 1-m intervals using a ϫ100 oil-immersion objective. Single-laser scan line interlacing was used to eliminate bleed through. Image J (National Institutes of Health) was used for the examination of images and evaluation of immunoreactivity. Images were digitally despeckled and contrast adjusted before slices through the cell of interest, including the nucleus, were superimposed for a better examination of immunoreactivity and to ensure that synaptic contacts were not contributing to the signal. TPH immunoreactivity was uniform throughout somata, extending into dendrites, and easily distinguishable from large, brighter punctate beads of retrograde label (see Fig. 3 , B-D,iii). Cells were divided into positively immunoreactive, immunonegative, or ambiguously stained groups for both GAD and TPH. Neurons were excluded from some analyses when data sets were incomplete. Any neurons with ambiguous immunochemical staining were excluded when properties were classified in terms of GAD/TPH staining. However, when opioid responses were examined in isolation, such neurons were not excluded, as indicated in the RESULTS.
Drugs. Stock solutions of all drugs were diluted to working concentrations using aCSF immediately before use and applied by superfusion. Opioid agonists were superfused in a random order. D-Phe-Cys-Tyr-DTrp-Arg-Pen-Thr-NH 2 (CTAP), Tyr-D-Ala-Gly-N-Me-Phe-Gly-ol enkephalin (DAMGO), deltorphin II, and orphanin-FQ (nociceptin, PheGly-Gly-Phe-Thr-Gly-Ala-Arg-Lys-Ser-Ala-Arg-Lys-Leu-Ala-Asn-Gln) were obtained from Auspep (Parkville, Victoria, Australia); baclofen and U-69593 were from Sigma (Sydney, NSW, Australia); and CGP-55846, ICI-174,864, and nor-binaltorphimine dihydrochloride (nor-BNI) were from Tocris Cookson (Bristol, UK).
Statistical analysis. Numeric data are expressed as means Ϯ SE. Comparisons were with Matlab or Prism software (Graphpad, San Diego, CA) using 2 -and Fisher's exact tests for differences among proportions and ANOVA for comparing current sizes between conditions. Two-tailed unpaired t-tests and Mann-Whitney tests were used when making other comparisons.
RESULTS

GAD and TPH immunoreactivity in the RVM.
Neurons immunoreactive for GAD, TPH, or both were found throughout the RVM. TPH-immunoreactive neurons were located mostly in the B1 and B3 serotonin-containing groups with only the very rostral B2 group present within the recording area. GAD-immunoreactive neurons were most abundant in the ventromedial medulla, immediately rostral to the inferior olive, and extending just beyond the rostral pole of the facial nucleus, coinciding with the rostrocaudal extent of recorded neurons. Neurons with ambiguous staining for serotonin or GAD were excluded from these analyses and, as previously reported (Zhang et al. 2006) , long-duration recordings produced equivocal post hoc immunohistochemical results for TPH in the RVM. Recording duration did not reduce GAD-like immunoreactivity, although TPH-like immunoreactivity was diminished, particularly in the somata of in-cells recorded for Ͼ24 min. All neurons recorded for longer than 20 min were therefore excluded from immunohistochemical analyses.
In some animals, tracer injections were made into the lumbar dorsal horn, and recordings were made from RVM neurons that were first identified as containing fluorescent nanospheres (77 neurons from 35 mice). In other animals, recordings were made from randomly selected neurons in animals that did not receive prior tracer injections ("random neurons," 178 neurons from 70 mice). Seventy-four percent (n ϭ 57/77) and 53% (n ϭ 95/178) of retrogradely labeled and random biocytin-filled neurons, respectively, were recovered for immunohistochemical staining (Fig. 1) .
We first compared the patterns of TPH and GAD staining in retrogradely labeled and randomly targeted neurons where immunoreactivity for both was discriminated. More retrogradely labeled neurons (57%, n ϭ 21/37) than random neurons (15%, n ϭ 8/52) were TPH immunoreactive (P Ͻ 0.0001; Fig. 2) . In contrast, similar proportions of retrogradely labeled (41%, n ϭ 15/37) and random (39%, n ϭ 20/52) neurons were GAD immunoreactive (P ϭ 0.9; Fig. 2) . A greater proportion of retrogradely labeled GAD-immunoreactive neurons (53%, n ϭ 8/15) compared with random GAD-immunoreactive neurons (5%, n ϭ 1/20) were also TPH immunoreactive (P ϭ 0.002; Fig. 2) .
GAD-and TPH-immunoreactive neurons in the RVM exhibit distinct cellular physiological properties.
A number of action potential characteristics varied with TPH immunoreactivity. As previously reported in rats (Kalyuzhny and Wessendorf 1999; Marinelli et al. 2005; Pan et al. 1990 Pan et al. , 1993 Pan et al. , 1997 Zhang and Hammond 2010; Zhang et al. 2006) , both retrogradely labeled and random neurons that were TPH immunoreactive had significantly longer action potential half-widths than those that were not TPH immunoreactive (Table 1 and Figs. 1 and 3) . Correspondingly, a greater proportion of retrogradely labeled and random neurons that were TPH immunoreactive displayed an inflection in the rate of the repolarization phase of the action potential (Table 1 and Figs. 1 and 3 ). Both retrogradely labeled and random neurons that were TPH immunoreactive were less likely to display a fast AHP and had a lower whole cell conductance (Table 1) . Other physiological characteristics, including the action potential firing rate in cell-attached mode before break-in, holding current, action potential amplitude, and slow AHP amplitude and half-width did not vary with TPH immunoreactivity (data not shown). No action potential or other physiological characteristics varied with GAD immunoreactivity (Table 1) .
Opioid responses of RVM neurons. Subpopulations of retrogradely labeled and random RVM neurons responded with outward currents to the -, ␦-, and -opioid receptor agonists DAMGO (3 M), deltorphin II (300 nM), and U-69593 (300 nM; Fig. 3 ). DAMGO (63%, n ϭ 124/196) produced an outward current in a greater proportion of neurons than deltorphin II (25%, n ϭ 42/169, P Ͻ 0.0001) or U-69593 (15%, n ϭ 27/153, P Ͻ 0.0001). DAMGO-, deltorphin II-, and U-69593-induced outward currents were observed in the combined presence of TTX (300 nM), 6-cyano-7-nitroquinoxaline-2,3-dione (5 M), and picrotoxin (100 M). DAMGO-induced outward current had a reversal potential of Ϫ102 Ϯ 2 mV (n ϭ 5) and was abolished by the addition of the selective -opioid receptor antagonist CTAP (1 M, n ϭ 9) or naloxone (1 M, n ϭ 22; Fig. 3, A, B, and D) . Deltorphin II-and U-69593-induced outward currents were reversed by the ␦-and -opioid receptor antagonists ICI-174864 (300 nM, n ϭ 5) and nor-BNI (300 nM, n ϭ 9), respectively (Fig. 3, A and B) . All neurons, including those neurons that did or did not respond to DAMGO, deltorphin II, or U-69593, responded with an outward current to the opiate receptor-like 1 agonist nociceptin (300 nM, 67 Ϯ 4 pA, n ϭ 115) or the GABA B receptor agonist baclofen (10 M, 44 Ϯ 5 pA, n ϭ 28; Fig. 3C ).
We next compared opioid responses in retrogradely labeled and random neurons. DAMGO produced an outward current in a greater proportion of retrogradely labeled neurons than deltorphin II and U69593 (65% vs. 12% and 22%, P Ͻ 0.0001 each; Fig. 4) . Similarly, DAMGO produced an outward current in a greater proportion of random neurons than deltorphin II and U69593 (71% vs. 32% and 11%, P Ͻ 0.0001 each; Fig. 4 ).
DAMGO produced an outward current in similar proportions of retrogradely labeled and random neurons (P ϭ 0.4; Fig. 4) . Deltorphin II produced an outward current in a greater proportion of random neurons than retrogradely labeled neurons (P ϭ 0.003; Fig. 4 ). U-69593 produced an outward current in similar proportions of retrogradely labeled and random neurons (P ϭ 0.08; Fig. 4 ). Of the DAMGO-responding neurons, a greater proportion of random neurons (35%, n ϭ 17/49) than retrogradely labeled neurons (8%, n ϭ 3/38) also responded to deltorphin II (P ϭ 0.004). Of the DAMGO-responding neurons, similar proportions of retrogradely labeled neurons (21%, n ϭ 9/42) and random neurons (13%, n ϭ 7/54) also responded to U-69593 (P ϭ 0.3).
Some other physiological properties varied with opioid responsiveness in retrogradely labeled and random neurons. Retrogradely labeled neurons that responded to DAMGO had longer-duration action potentials, were more likely to display an inflection in the repolarization of the action potential, and were less likely to display a fast AHP than those that did not respond to DAMGO (Table 1) . Random neurons that responded to deltorphin II had higher conductance, shorter-duration action potentials, did not display a hump on the action potential repolarizing phase, and always displayed a fast AHP compared with those that did not respond to deltorphin II (Table 1) . Finally, retrogradely labeled and random neurons that responded to U-69593 had longer-duration action potentials and were more likely to display an inflection on the action potential repolarizing phase than those not responding to U-69593 (Table 1) . 
TPH and GAD immunoreactivity vary with opioid responses.
We next examined whether opioid responsiveness was correlated with TPH immunoreactivity. A greater proportion of TPH-positive retrogradely labeled neurons responded to DAMGO (87%) compared with TPH-negative retrogradely labeled neurons (40%, P ϭ 0.004; Fig. 5A,i) . In contrast, similarly high proportions of TPH-positive (86%) and TPHnegative (63%) random neurons responded to DAMGO (P ϭ 0.5; Fig. 5A,ii) . Similarly, small proportions of TPH-positive (10%) and TPH-negative (31%) retrogradely labeled neurons (P ϭ 0.2) and TPH-positive (25%) and TPH-negative (37%) random neurons (P ϭ 0.7) responded to deltorphin II (Fig. 5A,i and ii). Similarly, small proportions of TPH-positive (29%) and TPH-negative (13%) retrogradely labeled neurons responded to U-69593 (P ϭ 0.4; Fig. 5A,i) . Similarly, small proportions of TPH-positive (25%) and TPH-negative (5%) random neurons responded to U-69593 (P ϭ 0.1; Fig. 5A ,ii). Proportions of TPH-positive and -negative neurons that responded to DAMGO, deltorphin II, and U-69593 did not differ between retrogradely labeled and random neurons (P ϭ 0.2-0.9).
We also examined whether opioid responsiveness was correlated with GAD immunoreactivity. A similarly high proportion of GAD-positive (67%) and GAD-negative (60%) retrogradely labeled neurons responded to DAMGO (P ϭ 0.9; Fig.  5B,i) . A greater proportion of GAD-positive random neurons responded to DAMGO (86%) compared with GAD-negative random neurons (58%, P ϭ 0.04; Fig. 5B,ii) . Similarly, small proportions of GAD-positive (21%) and GAD-negative (15%) retrogradely labeled neurons responded to deltorphin II (P ϭ 0.7; Fig. 5B,i) . Similarly, small proportions of GAD-positive (38%) and GAD-negative (26%) random neurons responded to deltorphin II (P ϭ 0.5; Fig. 5B,ii) . Similarly, small proportions of GAD-positive (29%) and GAD-negative (21%) retrogradely labeled neurons responded to U-69593 (P ϭ 0.7; Fig. 5B,i) . Whereas no GAD-positive random neurons responded to U-69593, a small proportion of GAD-negative random neurons (20%) did respond to U-69593 (P ϭ 0.04; Fig. 5B ,ii). Proportions of GAD-positive and -negative neurons that responded to DAMGO and deltorphin II did not differ between retrogradely labeled and random neurons (P ϭ 0.3-0.9). A greater proportion of GAD-positive retrogradely labeled neurons responded Physiological properties of different rostral ventromedial medulla (RVM) phenotypes [immunoreactivity for glutamate decarboxylase (GAD) and trytophan hydroxylase (TPH) as well as opioid responsiveness]. Properties are means (ϮSE) for conductance, action potential (AP) half-width of neurons, and percentage of neurons that spontaneously fired in the cell-attached mode (spontaneous APs), had a positive inflexion on the AP repolarizing phase (AP Hump), and a fast afterhyperpolarization (AHP); n represents the total number of neurons tested for each property. DAMGO, Tyr-D-Ala-Gly-N-Me-Phe-Gly-ol enkephalin. *P Ͻ 0.05; †P Ͻ 0.01; ‡P Ͻ 0.001.
to U-69593 than GAD-positive random neurons (P ϭ 0.02; Fig. 5B,i and ii) .
We finally examined both TPH and GAD immunoreactivity in subsets of these neurons (Fig. 6, A and B) . Similar proportions of retrogradely labeled neurons that were immunoreactive for GAD only, TPH only, both GAD and TPH, and neither GAD nor TPH responded to DAMGO (P ϭ 0.1), deltorphin II (P ϭ 0.6), and U-69593 (P ϭ 0.4). Statistical comparisons for random neurons could not be made because of the small numbers of responsive neurons with identified double labeling.
Sham surgery RVM neurons. In some animals, recordings were made from RVM neurons without prior identification of the presence of fluorescent nanospheres ("sham neurons," 36 neurons from 23 mice) in mice that received tracer injections into the lumbar dorsal horn. We compared these sham unidentified RVM neurons to random neurons that had not received spinal tracer microinjections to determine whether tracer injection surgery altered neuronal characteristics. There were no differences in the proportions of sham and random neurons that responded to DAMGO, deltorphin II, and U-69593 (P ϭ 0.95, 0.4, and 0.5). In the responding neurons, however, DAMGO produced an outward current that was greater in amplitude in Fig. 3 . Electrophysiological characterization of RVM neurons. A,i-D,i: current traces for four neurons during superfusion of the -, ␦-, and -opioid agonists Tyr-D-Ala-Gly-N-Me-Phe-Gly-ol enkephalin (DAMGO; 3 M), deltorphin II (Delt; 300 nM), and U-69593 (U69; 1 M), the ␦-and -opioid antagonists ICI-174864 (ICI; 300 nM) and nor-binaltorphimine dihydrochloride (nor-BNI; 300 nM), the opioid antagonist naloxone (Nalx; 1 M), and the GABA B agonist and antagonist baclofen (Bacl; 10 M) and CGP-55845 (CGP; 1 M) when neurons were voltage clamped at Ϫ60 mV. A,ii-C,ii: action potentials in the current-clamp mode for these neurons. Post hoc immunostaining for the neurons in A, B, and D is shown in Fig. 1, A, B , and D; the neuron in C was TPH immunoreactive and contained fluorescent nanospheres. Fig. 4 . The proportion of opioid-responding subtypes differs between spinally projecting and randomly selected RVM neurons. The bar chart displays the percentage of RVM neurons that responded to the -, ␦-, and -opioid agonists DAMGO, deltorphin II, and U-69593 in recordings from retrogradely labeled neurons from animals that received spinal tracer injections and randomly selected neurons from animals that did not receive spinal tracer injections. Values inside the bars indicate the number of responders, whereas those below the bars indicate the total number of neurons tested with each opioid agonist. ***P Ͻ 0.001 for the comparison of ␦-and -opioid responders to -opioid responders for retrogradely labeled and random neurons; ##P Ͻ 0.01 for the comparison of ␦-opioid responders between retrogradely labeled and random neurons. sham neurons than in random neurons (sham neurons: 57 Ϯ 9 pA and random neurons: 35 Ϯ 3 pA, P ϭ 0.002), suggesting there is subpopulation of RVM neurons in which the amplitude of the K ϩ conductance activated by the -opioid receptor is increased after surgery. In contrast, deltorphin II (random neurons: 39 Ϯ 5 pA and sham neurons: 45 Ϯ 15 pA, P ϭ 0.6) and U-69593 (random neurons: 23 Ϯ 5 pA and sham neurons: 38 Ϯ 12 pA, P ϭ 0.2) produced similar outward currents in random and sham neurons. Sham and random cells did not differ in physiological properties, including firing rates in the cell-attached mode, whole cell conductance, and action potential characteristics. Of the sham neurons that were recovered for immunostaining, 19% (n ϭ 5/27) were identified as containing fluorescent nanospheres.
Regional distribution of opioid-responsive neurons and GAD immunoreactivity within the RVM. While the anatomic locations of retrogradely labeled and random neurons were similar, there was some variation in the location of opioidresponsive neurons throughout the RVM (Fig. 7) . Random neurons that responded to U-69593 were located more medially than neurons that did not respond to U-69593 (14 Ϯ 4 vs. 83 Ϯ 11 m from the midline, P ϭ 0.01, n ϭ 9 and 55). Deltorphin II-responsive neurons tended to be more laterally located, although this was not significant (98 Ϯ 21 v. 68 Ϯ 14 m, P ϭ 0.08, n ϭ 24 and 79). Neurons responsive to DAMGO were distributed throughout the RVM both dorsoventrally and mediolaterally, although few neurons in the most caudal and rostral levels RVM were DAMGO responsive. GAD-immunoreactive neurons were found throughout the RVM, with a tendency to be located more rostrally, coincident with -opioid receptor distribution.
DISCUSSION
The present study demonstrated that substantial proportions of spinally projecting and nonprojecting neurons within the mouse RVM are directly inhibited by -opioids. Serotonergic projecting neurons and GABAergic nonprojecting neurons within the RVM were relatively homogenous in that most were directly inhibited by -opioids. In addition, a substantial subpopulation of -opioid-responding, GABAergic nonprojecting neurons were also inhibited by ␦-opioids. The other groups of RVM neurons displayed heterogeneous responses to -, ␦-, and -opioids. These findings indicate that -opioids modulate both GABAergic and non-GABAergic descending pathways from the RVM as well as GABAergic neurons within this brain region that likely do not all project to the spinal cord dorsal horn.
RVM neuronal phenotypes. In the present study, it was found that mouse RVM neurons with identified projections to the dorsal horn of the spinal cord had mixed phenotypes. RVM serotonergic neurons had a comparable anatomic distribution to those reported in mice by anatomic studies (Braz and Basbaum 2008; Vanegas et al. 1984) . Approximately half (57%) of the RVM-projecting neurons sampled in this study were identified as serotonergic using TPH immunoreactivity, which is slightly higher than in prior electrophysiological (36 -40%) (Finnegan et al. 2004; Marinelli et al. 2002 Marinelli et al. , 2005 Zhang and Hammond 2010; Zhang et al. 2006) and anatomic studies in the rat (27-30%) (Skagerberg and Bjorklund 1985) . A significant proportion of RVM-projecting neurons were GABAergic (41%) using immunoreactivity to GAD67, including some of the serotonergic neurons. While similar to a prior anatomic study (Kalyuzhny and Wessendorf 1998) , the pro- (2001), with distance from the bregma shown (in mm). Scale bars ϭ 500 m and 1 mm for detail sections and lower-powered images, respectively. portion of GABAergic projecting neurons found here was higher than that observed in a prior electrophysiological study in the rat (15%), which used GABA immunohistochemistry (Finnegan et al. 2004) , although it is possible that GABA is more easily dialyzed from the cell in whole cell recording owing to a smaller molecular mass. A substantial proportion of RVM-projecting neurons were neither serotonergic nor GABAergic, which suggests that other neurotransmitters, such as glutamate, may have a role in descending analgesic pathways (Kalyuzhny and Wessendorf 1998) .
Most of the random neurons in the present study were likely to be nonprojecting neurons, or local interneurons, because only 19% of randomly selected RVM neurons from animals that received lumbar dorsal horn tracer injections (sham neurons) were identified post hoc as being retrogradely labeled, as previously observed in the rat RVM (Marinelli et al. 2002) . We cannot, however, exclude the possibility that some of these randomly selected neurons project to deeper laminae of the spinal cord or different segmental levels to those targeted by tracer injections in the present study. In contrast to projecting neurons, few of these randomly selected RVM neurons were serotonergic (15%), which is in agreement with previous in vitro electrophysiological and anatomic studies in the rat (Marinelli et al. 2002; Potrebic et al. 1994) . Like the identified projecting neurons, a substantial proportion of the randomly selected neurons (39%) were GABAergic, but unlike the projecting neurons, very few of these were also serotonergic. These findings indicate that many nonprojecting neurons within the RVM are GABAergic or contain other, as yet to be identified neurotransmitter(s), such as glycine and glutamate, given that neurons in the RVM less frequently coexpress peptides than adjacent regions (Bowker and Abbott 1990) .
In addition to transmitter phenotypes, the passive and active membrane properties of serotonergic and GABAergic neurons in vitro in mice were similar to those previously reported for serotonergic and nonserotonergic neurons in rats (Kalyuzhny and Wessendorf 1999; Marinelli et al. 2005; Pan et al. 1990 Pan et al. , 1993 Pan et al. , 1997 Zhang and Hammond 2010; Zhang et al. 2006) . Similar to previous studies in the rat (Zhang et al. 2006; Zhang and Hammond 2010) , a large number of neurons did not display tonic or phasic discharge, and the proportions of spontaneously active neurons did not covary with immunochemical types or responses to selective opioids. It should be noted that further direct comparisons of action potential activity between rats and mice are difficult because the present study examined spontaneous activity only during cell-attached patch-clamp recording to avoid the effects of altered intracellular ionic composition that occur during the whole cell mode of recording. Membrane conductances in the mouse were also similar to those (reported as resistance) in rats, but a larger proportion of mouse than rat RVM neurons displayed a fast AHP (Zhang et al. 2006) .
Opioid sensitivity varies with the phenotype of RVM neurons. -Opioid receptor activation inhibited over half (62-65%) of the projecting and nonprojecting neurons within the mouse RVM, similar to prior studies in the rat (Marinelli et al. 2002; Zhang et al. 2006; Zhang and Hammond 2010) . In addition, ␦-and -opioid receptor activation inhibited smaller subpopulations of RVM neurons (12-32%), as in the rat RVM (Marinelli et al. 2002 (Marinelli et al. , 2005 . Unlike the rat, ␦-opioid inhibition was more frequent in nonprojecting neurons than in projecting neurons in the mouse RVM (Marinelli et al. 2005) . Furthermore, ␦-opioid-sensitive neurons were largely a subpopulation of the -opioid-sensitive neurons that did not project to the spinal cord, which provides a potential substrate for the /␦-opioid analgesic synergy observed in a previous study (Rossi et al. 1994 ) and the finding that both ␦-and -receptor agonists activate off-cells in the RVM in vivo (Harasawa et al. 2000) .
The -opioid-sensitive projecting and nonprojecting RVM neurons differed in serotonergic and GABAergic phenotypes: -opioids inhibited virtually all serotonergic projecting neurons and GABAergic nonprojecting neurons. In contrast, -opioids inhibited approximately half of the nonserotonergic projecting neurons and non-GABAergic neurons without identified projections to the spinal cord. This differs from the rat, where -opioids inhibit ϳ60 and 85% of serotonergic and nonserotonergic projecting neurons, respectively (Marinelli et al. 2002) . The present findings indicate that -opioids exert a proportionally greater and more homogeneous control over serotonergic projecting neurons and that GABAergic neurons that do not project to the spinal dorsal horn within the mouse RVM. Nonetheless, -opioids inhibit a diverse range of neuronal types within the RVM, which is consistent with the finding that -opioid receptor 1 is expressed in both TPH-and GAD-containing RVM neurons that project to the spinal cord (Kalyuzhny and Wessendorf 1998; Wang and Wessendorf 1999) .
Patch-clamp studies of opioid responses of RVM have all been performed using rats and mice less than 3-4 wk old (Marinelli et al. 2002 (Marinelli et al. , 2005 Zhang et al. 2006; Zhang and Hammond 2010) . Electrical stimulation of RVM neurons can either inhibit or facilitate responses of deep dorsal horn neurons to noxious mechanical stimuli, but facilitation predominates up to P21, and electromyographic responses are exclusively facilitated (Hathway et al. 2009) . It is therefore possible that the membrane properties and opioid responses reported here represent a neonatal pattern that transforms after P21. However, the opioid responses in the neonatal mouse RVM are consistent with those we and others have observed among neonatal serotonergic and nonserotonergic RVM projecting neurons in the rat (Marinelli et al. 2002 (Marinelli et al. , 2005 Zhang et al. 2006; Zhang and Hammond 2010) . These responses are consistent with opioid receptor expression in adult rats determined by in situ hybridization and immunohistochemistry (Kalyuzhny et al. 1996; Wessendorf 1998, 1999; Marinelli et al. 2005; Wang and Wessendorf 1999) , suggesting that the expression of opioid responses among RVM neurons is established before the adult function of the region to control spinal excitability.
Functional implications. It was originally proposed that -opioids indirectly activate (disinhibit) the descending antinociceptive pathway by inhibiting GABAergic interneurons, which synapse onto spinally projecting serotonergic RVM neurons. Indeed, in the present study, we have provided evidence that nonprojecting RVM GABAergic neurons form a relatively homogeneous population that is directly inhibited by -opioids, many of which are also inhibited by ␦-opioids. While the targets of these neurons were not identified in this study, it is possible that they provide the GABAergic input onto RVM-projecting neurons, as observed by others (Finnegan et al. 2004) , although GABAergic inputs from other brain structures cannot be excluded (Reichling and Basbaum 1990 ).
More recent in vivo studies, however, have demonstrated little inhibitory connectivity between different functional classes of RVM neurons during noxious stimulation of the tail (Cleary et al. 2008; Fields et al. 1991; Heinricher et al. 2009 ). This suggests that -opioids do not disinhibit the descending pathway but instead directly inhibit distinct, spinally projecting pathways, as suggested by others (Cleary et al. 2008 ). Our present and previous findings that spinally projecting neurons of different phenotypes are heterogeneous with respect to opioid receptor subtype responsiveness are also consistent with this assertion and suggest that these pathways may be serotonergic and GABAergic (Marinelli et al. 2002) . Moreover, the present findings suggest that opioid responsiveness is not confined to spinally projecting neurons of either of the major neurotransmitter phenotypes identified in the RVM.
The heterogeneity in RVM opioid responsiveness and phenotype observed in the present study might also account for the plasticity of on-and off-cell responses to different noxious stimuli observed by others (Ellrich et al. 2000 (Ellrich et al. , 2001 Miki et al. 2002) . While some studies have shown that the analgesia induced by RVM electrical stimulation and morphine microinjection is blocked by systemic and intrathecal serotonergic antagonists (Azami et al. 1982; Hammond and Yaksh 1984; Jensen and Yaksh 1986) , the role of spinally projecting serotonergic RVM neurons in analgesia remains unresolved (Braz and Basbaum 2008; Mason 2005 ; also see the Introduction). It is unclear what functional role is played at the spinal level by -opioid-sensitive, serotonergic projecting neurons observed in this and previous studies (Marinelli et al. 2002 (Marinelli et al. , 2005 Zhang et al. 2006; Zhang and Hammond 2010) , although serotonergic neurons may be responsible for the state-dependent changes in spinal reflexes (Fornal et al. 1985) that are less obvious in anesthetized preparations. We cannot predict whether these projecting neurons are anti-or pronociceptive at the spinal level. It is possible these neurons have an analgesic action and that direct postsynaptic inhibition is overcome by presynaptic disinhibition of GABAergic inputs by -opioids (Finnegan et al. 2004) . It is also possible that these -opioid-responsive neurons are spinally projecting neurons that facilitate nociception (Zhou and Gebhart 1990, 1997) , with inhibition resulting in analgesia.
